shares of biomarin pharmaceutical inc bmrn were down about 60 in premarket trading on monday after bridgebio pharma inc bbio shared positive phase 2 clinical data about its experimental dwarfism drug which could compete with biomarin’s voxzogo if and when it’s approved biomarin received food and drug administration approval for voxzogo as a treatment for some children 5 years old and older with achondroplasia in late 2021 the drug generated about 169 million in sales last year biomarin’s stock is down 10 over the past three months while the broader sp 500 spx has declined 02